5
13
↑5
↓13
—0
Evidence suggests Melatonin maydecreaseSleep latency.
16 studies (18 claims)
Typical dose 6 mg
Exact normalized-entity scope. Exact scope. Claims must match the selected normalized intervention and endpoint IDs; signal links are not expanded. Direction describes the stored endpoint phrase and is not a benefit/harm judgement.
18 of 18
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| melatonin | Decreases - reduced | sleep latency | Human | persons with ID and chronic insomnia | 5 mg (2.5 mg for those under 6 years old) daily. | Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia.cited 11× |
| melatonin | Increases - tended to improve | sleep latency | Human | patients with CF | 3 mg melatonin daily. | Melatonin improves sleep and reduces nitrite in the exhaled breath condensate in cystic fibrosis--a randomized, double-blind placebo-controlled study.cited 26× |
| melatonin | Decreases - showed improvement | sleep latency | Human | children with ADHD and insomnia | 3 to 6 mg administered within a few hours of bedtime. | Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder.cited 61× |
| melatonin | Decreases - can shorten | sleep latency | Human | dementias and PD | Not specified | Insomnia in central neurologic diseases--occurrence and management.cited 70× |
| melatonin | Decreases - improved effect | sleep latency | Human | participants aged 3 months to 18 years who had both a visual impairment and a sleep disorder | Not available | Therapeutic options in the management of sleep disorders in visually impaired children: a systematic review.cited 7× |
| Melatonin | Decreases - demonstrated significant efficacy in reducing | sleep latency | Human | subjects with primary sleep disorders | Not specified (higher doses showed greater effects). | Meta-analysis: melatonin for the treatment of primary sleep disorders.cited 269× |
| Melatonin | Decreases - demonstrated greater effects on decreasing | sleep latency | Human | — | Not specified (higher doses showed greater effects). | Meta-analysis: melatonin for the treatment of primary sleep disorders.cited 269× |
| Melatonin | Decreases - exhibited a positive response, with reduced | sleep latency | Human | ADHD patients | Not specified | To sleep or not to sleep: a systematic review of the literature of pharmacological treatments of insomnia in children and adolescents with attention-deficit/hyperactivity disorder.cited 27× |
| melatonin | Decreases - decreased | sleep latency | Human | prepubertal, developmentally normal children aged 6-11 years with epilepsy | 9-mg sustained-release melatonin, administered once daily. | Melatonin improves sleep in children with epilepsy: a randomized, double-blind, crossover study.cited 53× |
| melatonin (MLT) | Decreases - significant | sleep latency | Human | — | Not specified | Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action.cited 55× |
| melatonin | Decreases - results in decrease | sleep latency (SL) | Human | patients undergoing laparoscopic cholecystectomy (LC) | 6 mg melatonin tablets taken 45 minutes before sleep. | Efficacy of melatonin on sleep quality after laparoscopic cholecystectomy.cited 17× |
| melatonin | Decreases - significantly improved | sleep latency | Human | — | Not specified | Pharmacologic Treatments for Sleep Disorders in Children: A Systematic Review.cited 25× |
| Melatonin | Increases - improved | sleep latency | Human | Patients with rare MTNR1B variants | — | Circadian, Sleep and Caloric Intake Phenotyping in Type 2 Diabetes Patients With Rare Melatonin Receptor 2 Mutations and Controls: A Pilot Study. |
| Melatonin | Increases - improved | sleep latency | Human | T2D MTNR1B variant carriers | — | Circadian, Sleep and Caloric Intake Phenotyping in Type 2 Diabetes Patients With Rare Melatonin Receptor 2 Mutations and Controls: A Pilot Study. |
| Melatonin | Decreases - significantly reduced | sleep latency | Human | participants with MCI/mild AD dementia | Not specified | Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review.cited 72× |
| melatonin | Increases - observed | sleep latency | Human | ASD | Not specified | Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder.cited 49× |
| melatonin | Decreases - reduces | sleep latency | Human | — | 0.5–3 mg (children), 3–5 mg (adolescents), 1–5 mg (adults), 1–6 mg (elderly). | Regulatory aspects and evidences of melatonin use for sleep disorders and insomnia: an integrative review.cited 8× |
| melatonin | Increases - significantly improved | sleep latency | Human | breast cancer patients undergoing hormone therapy | 6 mg daily | Melatonin Aids in Treating Mood and Sleep Problems Resulting from Hormonal Therapy in Breast Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. |